US › Healthcare

Humacyte Inc (HUMA)

US · Healthcare · Biotechnology

$0.58+0.89%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$406,000

Revenue YoY

+34.9%

Net profit

$-36.8M

EPS

$-0.16

EPS estimate

$-0.10

Net margin

-9,064.5%

EPS came in at -0.16 against a street estimate of -0.10 — a miss of 60.0%.

Key statistics

Market cap

$157.7M

Forward P/E

35.8

P/B

5.04

Book value

$0.11

EPS (TTM)

$-0.52

52-week high

$2.55

52-week low

$0.53

50-day MA

$0.66

200-day MA

$0.93

Beta

2.45

Analyst view

Analysts rate Humacyte Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $1.85.

Shareholding

Insiders

5.61%

Institutions

26.65%

Largest institutional holders

Fund	Stake
BlackRock Inc	4.43%
Antipodes Partners Limited	3.64%
Vanguard Capital Management, LLC	2.58%
Great Point Partners LLC	1.35%
Geode Capital Management, LLC	1.32%
State Street Corp	1.10%
UBS Group AG	1.00%
Woodline Partners LP	0.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Humacyte Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.